drug
ERTUGLIFLOZIN
Marketedupdated 3mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Type 2 Diabetes
all catalysts(4)
Trials studying ERTUGLIFLOZIN
- phase4DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
- phase1Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.
- phase3Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
- phase2Ertugliflozin in Chronic Heart Failure
- phase2ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
- phase4Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
- phase3Ertugliflozin for Functional Mitral Regurgitation
- EP1Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 13, 2030
~3.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 13, 2030compositionUS 80805803.9y
- Jul 13, 2030compositionUS 80805803.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that